Both Neon Therapeutics Inc. (NASDAQ:NTGN) and Aclaris Therapeutics Inc. (NASDAQ:ACRS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins

Return on Equity

Return on Assets

Neon Therapeutics Inc.

0.00%

-545.4%

-69.6%

Aclaris Therapeutics Inc.

-1,315.56%

-62.8%

-55.6%

Liquidity

The Current Ratio of Neon Therapeutics Inc. is 13 while its Quick Ratio stands at 13. The Current Ratio of rival Aclaris Therapeutics Inc. is 6.5 and its Quick Ratio is has 6.5. Neon Therapeutics Inc. is better equipped to clear short and long-term obligations than Aclaris Therapeutics Inc.

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts. In addition, it is developing JAK inhibitors, including ATI-50001 that has completed Phase I clinical trial for the oral treatment of alopecia totalis and alopecia universalis; and ATI-50002, which has completed Phase I clinical trial for the topical treatment of patchy autoimmune dermatologic condition. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Disclaimer: StocksBeat inform you that the data in this website is not necessarily real-time nor accurate. All prices are not provided by exchanges and prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Stocksbeat doesn`t bear any responsibility for any trading losses you might incur as a result of using the data.